1[3]James EFR. Martindale Pharmacopoeia. 31st edition[M]. London: The Royal Pharmaceutical Society，1996:388.
2[5]Rapeport WG， Mendelo AD， French G， et al. Plasma protein binding and CSF concentration of valproic acid in man following acute oral drug[J]. Br J Clin Pharmac，1983，16:356.
3scher W.Basic pharmacology of valproate:a review after 35 years of clinical use for the treatment of epilepsy[J].CNS Drugs,2002,16:669-694.
4Perucca E.Pharmacological and therapeutic properties of valproate:a summary after 35 years of clinicalexperience[J].CNS Drugs,2002,16:695-714.
5Clarkson A,Choonara I.Surveillance for fatal suspected adverse drug reactions in the UK [J].Arch Dis Child,2002,87(6):462.
6Johnson TN.The development of drug etabolizing enzymes and their influence on the susceptibility to adverse drug reactions in children [J].Toxicology,2003,192(1):37.
7Banerjea MC,Diener W,Kutschke G,et al.Pro-and anticoagulatory factors under sodium valproate-therapy in children [J].Neuropediatrics,2002,33(4):215.
8Tanaka E.Clinically significant pharmacokinetic drug interactions between antiepileptic drugs[J].J Clin Pharmacol Ther,1999,24:87-92.
10Grillo MP,Chiellini G,Tonelli M,et al.Effect of alpha-fluorination of valproic acid on valproyl-Sacyl- CoA formation in vivo in rats[J].Drug Metab Dispos,2001,29:1210-1215.
